| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
|
J Clin Oncol
|
2011
|
4.53
|
|
2
|
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
|
Clin Cancer Res
|
2012
|
3.36
|
|
3
|
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
|
J Clin Oncol
|
2008
|
2.65
|
|
4
|
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
|
J Clin Oncol
|
2011
|
2.46
|
|
5
|
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
|
J Clin Oncol
|
2006
|
2.35
|
|
6
|
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
|
Clin Cancer Res
|
2009
|
2.30
|
|
7
|
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
|
Mol Cancer Ther
|
2012
|
1.72
|
|
8
|
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2008
|
1.34
|
|
9
|
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.
|
Clin Cancer Res
|
2008
|
1.21
|
|
10
|
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
|
J Hematol Oncol
|
2014
|
1.20
|
|
11
|
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
1.19
|
|
12
|
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.
|
Oncoimmunology
|
2013
|
1.16
|
|
13
|
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.
|
Breast Cancer Res
|
2003
|
1.03
|
|
14
|
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
|
Clin Cancer Res
|
2004
|
1.01
|
|
15
|
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
|
Clin Cancer Res
|
2007
|
1.01
|
|
16
|
Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
|
Nat Clin Pract Oncol
|
2007
|
1.01
|
|
17
|
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
|
Clin Cancer Res
|
2004
|
1.00
|
|
18
|
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
|
Clin Cancer Res
|
2014
|
0.95
|
|
19
|
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
|
Clin Cancer Res
|
2005
|
0.94
|
|
20
|
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
|
J Clin Oncol
|
2003
|
0.92
|
|
21
|
The role of mTOR inhibitors for treatment of sarcomas.
|
Curr Oncol Rep
|
2007
|
0.91
|
|
22
|
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
|
Clin Cancer Res
|
2007
|
0.91
|
|
23
|
Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapy.
|
BMC Dermatol
|
2006
|
0.88
|
|
24
|
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
|
Cancer Chemother Pharmacol
|
2006
|
0.87
|
|
25
|
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
|
Semin Oncol
|
2003
|
0.87
|
|
26
|
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.85
|
|
27
|
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
0.85
|
|
28
|
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
|
Cancer Chemother Pharmacol
|
2007
|
0.85
|
|
29
|
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.84
|
|
30
|
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
|
Clin Cancer Res
|
2006
|
0.84
|
|
31
|
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
|
Cancer
|
2010
|
0.83
|
|
32
|
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
|
Clin Cancer Res
|
2003
|
0.83
|
|
33
|
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2008
|
0.83
|
|
34
|
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
|
Eur J Cancer
|
2013
|
0.82
|
|
35
|
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
|
Clin Cancer Res
|
2005
|
0.81
|
|
36
|
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
|
Clin Cancer Res
|
2009
|
0.81
|
|
37
|
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.81
|
|
38
|
Novel apoptosis inducing agents in cancer therapy.
|
Curr Probl Cancer
|
2005
|
0.81
|
|
39
|
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.81
|
|
40
|
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
|
Clin Cancer Res
|
2008
|
0.81
|
|
41
|
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
|
Drug Metab Dispos
|
2013
|
0.81
|
|
42
|
Development of novel alkylating drugs as anticancer agents.
|
Curr Opin Investig Drugs
|
2004
|
0.80
|
|
43
|
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.79
|
|
44
|
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors.
|
Am J Clin Oncol
|
2009
|
0.79
|
|
45
|
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.79
|
|
46
|
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
|
Cancer Chemother Pharmacol
|
2008
|
0.79
|
|
47
|
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
|
Cancer Chemother Pharmacol
|
2012
|
0.78
|
|
48
|
The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
|
J Clin Oncol
|
2002
|
0.77
|
|
49
|
Management of high risk metastatic prostate cancer: the case for novel therapies.
|
J Urol
|
2006
|
0.76
|
|
50
|
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2003
|
0.76
|
|
51
|
Castration-resistant prostate cancer--hormone therapy redux.
|
J Clin Oncol
|
2010
|
0.75
|
|
52
|
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
|
Cancer Chemother Pharmacol
|
2009
|
0.75
|
|
53
|
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
|
Invest New Drugs
|
2004
|
0.75
|
|
54
|
Novel therapies for renal cell carcinoma.
|
Cancer Treat Res
|
2003
|
0.75
|
|
55
|
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.
|
J Urol
|
2004
|
0.75
|